Brian MBA - Coeptis Therapeutics Chief Officer
| COEP Stock | USD 0.20 0.01 5.26% |
Executive
Brian MBA is Chief Officer of Coeptis Therapeutics
| Age | 38 |
| Address | 105 Bradford Road, Wexford, PA, United States, 15090 |
| Phone | (724) 934-6467 |
| Web | https://coeptistx.com |
Coeptis Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.8735) % which means that it has lost $1.8735 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8129) %, meaning that it created substantial loss on money invested by shareholders. Coeptis Therapeutics' management efficiency ratios could be used to measure how well Coeptis Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/30/2024, Return On Tangible Assets is likely to grow to -3.66. In addition to that, Return On Capital Employed is likely to grow to -4.02. At this time, Coeptis Therapeutics' Total Current Liabilities is relatively stable compared to the past year. As of 11/30/2024, Liabilities And Stockholders Equity is likely to grow to about 9.6 M, while Non Current Liabilities Total is likely to drop slightly above 1.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sai Iyer | LMF Acquisition Opportunities | N/A | |
| Dolly Tyan | Aditxt Inc | N/A | |
| Matthew MD | Cingulate | 60 | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Tom Mullen | LMF Acquisition Opportunities | N/A | |
| Joerg Heyer | Palisade Bio | N/A | |
| Ana Rodriguez | Dyadic International | N/A | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Mylene Touboul | Clearmind Medicine Common | N/A | |
| Jose MD | Allarity Therapeutics | 67 | |
| Dr D | Aditxt Inc | N/A | |
| Alexander Epshinsky | Allarity Therapeutics | 41 | |
| Ryker Willie | Palisade Bio | N/A | |
| Sandra Vedrick | Revelation Biosciences | N/A | |
| Thomas Dalton | Cingulate | N/A | |
| Yong Yu | Genelux Common | 53 | |
| Stephen McAndrew | Sonnet Biotherapeutics Holdings | 70 | |
| Doug BA | Dyadic International | N/A | |
| Lourie Zak | Genelux Common | 61 | |
| Pr MD | Genelux Common | 79 | |
| Tim Varacek | LMF Acquisition Opportunities | N/A | |
Management Performance
| Return On Equity | -14.81 | ||||
| Return On Asset | -1.87 |
Coeptis Therapeutics Leadership Team
Elected by the shareholders, the Coeptis Therapeutics' board of directors comprises two types of representatives: Coeptis Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coeptis. The board's role is to monitor Coeptis Therapeutics' management team and ensure that shareholders' interests are well served. Coeptis Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coeptis Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Sheehy, CoFounder Secretary | ||
| Daniel Yerace, VP CoFounder | ||
| Gary Conte, VP Marketing | ||
| David Mehalick, Chairman, CoFounder | ||
| Brian MBA, Chief Officer | ||
| MSc MD, CSO Officer |
Coeptis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Coeptis Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -14.81 | ||||
| Return On Asset | -1.87 | ||||
| Current Valuation | 8.7 M | ||||
| Shares Outstanding | 39.72 M | ||||
| Shares Owned By Insiders | 18.53 % | ||||
| Shares Owned By Institutions | 4.05 % | ||||
| Number Of Shares Shorted | 245.17 K | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 45.68 X | ||||
| Gross Profit | 75 K |
Pair Trading with Coeptis Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Coeptis Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coeptis Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Coeptis Stock
| 0.57 | HLN | Haleon plc | PairCorr |
| 0.55 | ELAN | Elanco Animal Health | PairCorr |
| 0.51 | ZTS | Zoetis Inc | PairCorr |
| 0.44 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.41 | TAK | Takeda Pharmaceutical | PairCorr |
The ability to find closely correlated positions to Coeptis Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Coeptis Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Coeptis Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Coeptis Therapeutics to buy it.
The correlation of Coeptis Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Coeptis Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Coeptis Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Coeptis Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.